Citadel Advisors’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Citadel Advisors’s Portfolio SCMP Stock Details SCMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-13,600	Closed	-$244K	–	9188
2017 Q4	$244K	Buy	+13,600	New	+$167K	﹤0.01%	6792
2016 Q1	–	Sell	-2,200	Closed	-$38K	–	8750
2015 Q4	$38K	Sell	2,200 -7,300	-77%	-$131K	﹤0.01%	7518
2015 Q3	$189K	Buy	+9,500	New	+$218K	﹤0.01%	6231

Other funds holding SCMP

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

AIM

Advantage Investment Management Cedar Rapids, Iowa $128M AUM 0.94% 1-Year Est. Return

Citadel Advisors's SCMP Position: Q1 2017 in Review

Citadel Advisors sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2017, closing a stake of 61,524 shares — an estimated $834K sold.

Citadel Advisors first reported a position in SCMP in Q2 2013 and held it in 12 quarters. The position peaked at $1.44M in Q1 2015. 167 funds tracked by Wall St. Rank hold SCMP as of Q1 2017.

Citadel Advisors reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
Citadel Advisors sold 61,524 Sucampo Pharmaceuticals, Inc. shares in Q1 2017, an estimated $834K.
Citadel Advisors first reported a position in Sucampo Pharmaceuticals, Inc. in Q2 2013 and held it in 12 quarters.
Citadel Advisors's Sucampo Pharmaceuticals, Inc. position peaked at $1.44M in Q1 2015.
167 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2017.

Based on Citadel Advisors's 13F filing for Q1 2017, filed 12 May 2017.